| Home > For doctors > Audit |
![]() |
Use of Ramipril |
![]() |
2000-2001
Patients with cardiovascular and diabetic disease
The Primary Health Care Team will start to implement the Heart Outcomes Prevention Evaluation (HOPE) study, together with the Micro-Hope study. This study presented at the 21st Congress of the European Society of Cardiology produced striking results in cardiovascular and diabetic patients treated with ACE-inhibitor Ramipril.
Results:
| HOPE | MICRO-HOPE | |
| Cardiovascular death reduced | 26% | 37% |
| MI reduced | 29% | 22% |
| Stroke reduced | 32% | 33% |
Evidence suggests this has added benefits to the above
Cycle 1
| Focus | Steps to be taken | Targets | Time scale | Resources | Success criteria |
|
|
Prescribe ramipril | 12 months from April 2001 | Dr / Nurse / Secretarial time | Computer search in April 2002 to ascertain percentage who have been prescribed ramipril |
Cycle 2003 |
December 2003
Patients with cardiovascular and diabetic disease
The Primary Health Care Team will start to implement the Heart Outcomes Prevention Evaluation (HOPE) study, together with the Micro-Hope study. This study presented at the 21st Congress of the European Society of Cardiology produced striking results in cardiovascular and diabetic patients treated with ACE-inhibitor Ramipril.
|
|
HOPE |
MICRO-HOPE |
|
Cardiovascular death reduced |
26% |
37% |
|
MI reduced |
29% |
22% |
|
Stroke reduced |
32% |
33% |
Evidence suggests this has added benefits to the above
Brent Smith
Brad Cheek 2000